What's on this Page
What is Ranibizumab
Ranibizumab is a recombinant humanized monoclonal antibody fragment designed to bind to all active isoforms of vascular endothelial growth factor (VEGF).
It is approved for the treatment of patients with macular edema after retinal vein occlusion (RVO), neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy, and myopic choroidal neovascularization (CNV).
Inhibition of VEGF with ranibizumab results in blockage of both vessel permeability and angiogenesis.
Ranibizumab was FDA-approved in June 2006.
Brand Name
Lucentis
Indications
- choroidal neovascularization (CNV)
- diabetic macular edema
- diabetic retinopathy
- macular degeneration
- macular edema following retinal vein occlusion
For the treatment of neovascular (wet) age-related macular degeneration (AMD)
Side Effects
- anemia
- antibody formation
- arthralgia
- atrial fibrillation
- blepharitis
- blurred vision
- cataracts
- conjunctival hyperemia
- constipation
- cough
- endophthalmitis
- gastroesophageal reflux
- headache
- hypercholesterolemia
- hyperemia
- impaired wound healing
- influenza
- injection site reaction
- lacrimation
- myocardial infarction
- nausea
- ocular hemorrhage
- ocular hypertension
- ocular infection
- ocular inflammation
- ocular irritation
- ocular pain
- ocular pruritus
- peripheral edema
- peripheral neuropathy
- pharyngitis
- renal failure (unspecified)
- retinal detachment
- sinusitis
- stroke
- thromboembolism
Monitoring Parameters
- intraocular pressure
Contraindications
- breast-feeding
- children
- geriatric
- glaucoma
- increased intraocular pressure
- infants
- neonates
- ocular infection
- ocular surgery
- pregnancy
Interactions
There are no drug interactions associated with Ranibizumab products.
